FUD transiently decreased IOP in mice injected with Ad5-TGFβ2 viral vector. by Jennifer A. Faralli (4907311)

“…IOP then returned to baseline pre-FUD injection levels on Day 20 (5 days after injection). n = 10, 9 and 8 for TGFβ2 + FUD, TGFβ2 + PBS and TGFβ2 + mFUD treated eyes respectively. …”

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

“…<b><i>Methods:</i></b> Thirty-three patients with HAE with C1-inhibitor deficiency, belonging to a single family, participated in a management program coordinated by an allergist/immunologist. …”

Probability of release is decreased by hydrophobic mutations. by Matthew R. Bowers (8423115)

Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

“…A375 melanoma cells were treated with 0.25 μM, 0.5 μM, or 1.0 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for (C) 24 h and (D) 48 h and analyzed for clonogenic survival (* represents when 12-, 14-, and 16-TPP were significant relative to 5-TPP and 8-TPP; Ψ represents when 10-TPP was significant relative to 5-TPP and 8-TPP; p < 0.05; n = 3 from 2 separate experiments; N = 6). …”

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”

Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

ROS and superoxide decrease in the dormant form of mycobacteria. by Amar Yeware (7115063)

PFKFB3-4+5 knockdown leads to decreased cell growth and colony formation. by Ulli Heydasch (11091062)

FTY720 treatment decreased phosphorylation of AKT, ERK, and c-myc. by Laura L. Stafman (6577184)

“…(B) Immunoblotting for the activated form of ERK1/2 –phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187)–and total ERK1/2 revealed a decrease in phospho-ERK1/2 with no accompanying change in total ERK1/2, indicating a decrease in ERK signaling with FTY720 treatment. …”

Decreased thrombin activity levels in PAR KO following 24 hours following ischemia. by Efrat Shavit-Stein (3186678)

“…Levels are significantly higher in WT mice in slice #3 and in slices #5 and #6 representing the ischemic core (two-way ANOVA with Sidak’s post-hoc analysis). …”

EtOH decreased ΔΨm in a subset of esophageal keratinocytes. by Prasanna M. Chandramouleeswaran (3176268)

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…(d) Noise-evoked activity rates at different noise intensities for chronically tracked PV cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 31 neurons, mean ± SE). Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 49.6, <i>p</i> = 2.6 × 10⁻¹², condition: intensity interaction F = 1.94, <i>p</i> = 0.02, nested ANOVA (mouse nested within session), F = 56.5, <i>p</i> = 8.8 × 10⁻¹⁴, condition: intensity interaction F = 3.5, <i>p</i> = 3.5 × 10⁻⁰⁵). …”

SARS-CoV-2-specific CD4 and cTfh responses decrease in magnitude in late convalescence. by Sushma Boppana (7181300)

Met decreases MYH1/2 and p21 expression and increases Myf5 and MyoD levels in myotubes. by Eleonora Maniscalco (14599854)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Nrf2 activation decreases PMN ROS production in response to zymosan. by Doumet Georges Helou (7255823)

ENaC activity is decreased in oocytes expressing wild type S protein. by Germán Ricardo Magaña-Ávila (18446799)

Disruption of putative host factor LGMN decreases SARS-CoV-2 viral entry. by Ravi K. Dinesh (21736629)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Dysfunction of <i>ERG251</i> activates a Zinc transporter contributing to decreased azole susceptibility. by Xin Zhou (54275)

Subjects: